OncoTherapy Science, Inc. (FRA:30O)

OncoTherapy Science Statistics

Total Valuation

FRA:30O has a market cap or net worth of EUR 39.40 million. The enterprise value is 30.12 million.

Market Cap	39.40M
Enterprise Value	30.12M

Important Dates

The next estimated earnings date is Friday, February 6, 2026.

Earnings Date	Feb 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	338.64M
Shares Outstanding	n/a
Shares Change (YoY)	+20.81%
Shares Change (QoQ)	+11.71%
Owned by Insiders (%)	8.98%
Owned by Institutions (%)	1.26%
Float	302.77M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.16
PB Ratio	4.16
P/TBV Ratio	4.16
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.34
EV / Sales	5.69
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.36

Financial Position

The company has a current ratio of 8.65

Current Ratio	8.65
Quick Ratio	7.89
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-742.03

Financial Efficiency

Return on equity (ROE) is -62.41% and return on invested capital (ROIC) is -35.08%.

Return on Equity (ROE)	-62.41%
Return on Assets (ROA)	-26.63%
Return on Invested Capital (ROIC)	-35.08%
Return on Capital Employed (ROCE)	-43.21%
Revenue Per Employee	117,145
Profits Per Employee	-101,093
Employee Count	47
Asset Turnover	0.55
Inventory Turnover	9.96

Taxes

In the past 12 months, FRA:30O has paid 11,518 in taxes.

Income Tax	11,518
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -33.45% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-33.45%
50-Day Moving Average	0.11
200-Day Moving Average	0.13
Relative Strength Index (RSI)	45.02
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:30O had revenue of EUR 5.51 million and -4.75 million in losses. Loss per share was -0.02.

Revenue	5.51M
Gross Profit	-2.50M
Operating Income	-4.27M
Pretax Income	-4.74M
Net Income	-4.75M
EBITDA	n/a
EBIT	-4.27M
Loss Per Share	-0.02

Balance Sheet

The company has 9.65 million in cash and n/a in debt, giving a net cash position of 9.65 million.

Cash & Cash Equivalents	9.65M
Total Debt	n/a
Net Cash	9.65M
Net Cash Per Share	n/a
Equity (Book Value)	9.47M
Book Value Per Share	0.03
Working Capital	9.60M

Cash Flow

In the last 12 months, operating cash flow was -4.39 million and capital expenditures -345,553, giving a free cash flow of -4.73 million.

Operating Cash Flow	-4.39M
Capital Expenditures	-345,553
Free Cash Flow	-4.73M
FCF Per Share	n/a

Margins

Gross margin is -45.40%, with operating and profit margins of -77.62% and -86.30%.

Gross Margin	-45.40%
Operating Margin	-77.62%
Pretax Margin	-86.09%
Profit Margin	-86.30%
EBITDA Margin	n/a
EBIT Margin	-77.62%
FCF Margin	n/a

Dividends & Yields

FRA:30O does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.81%
Shareholder Yield	-20.81%
Earnings Yield	-12.06%
FCF Yield	-12.02%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:30O has an Altman Z-Score of -3.9 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.9
Piotroski F-Score	4